概述

  • 产品名称Anti-cGMP抗体
    参阅全部 cGMP 一抗
  • 描述
    兔多克隆抗体to cGMP
  • 特异性The product is specific for cGMP and does not cross-react with 5'-AMP, 5'-ADP, 5'-ATP, cAMP, Guanosine, 5'-GMP, 5'-GDP and 5'-GTP.
  • 经测试应用适用于: IHC-FoFr, RIA, ICC/IFmore details
  • 种属反应性
    与反应: Human
  • 免疫原

    cGMP-2'-O-HS conjugated to BSA.

性能

应用

Our Abpromise guarantee covers the use of ab12416 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

应用 Ab评论 说明
IHC-FoFr
RIA
ICC/IF
  • 应用说明IHC-FoFr: 1/200(PMID 19666575).
    RIA: 1/10.


    Not yet tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • 靶标

    • 相关性Cyclic guanosine monophosphate (cGMP) serves as a second messenger in a manner similar to that observed with cAMP. Peptide hormones, such as the natriuretic factors, activate receptors that are associated with membrane-bound guanylate cyclase (GC). Receptor activation of GC leads to the conversion of GTP to cGMP. Nitric oxide (NO) also stimulates cGMP production by activating soluble GC, perhaps by binding to the heme moiety of the enzyme. Similar to cAMP, cGMP mediates most of its intracellular effects through the activation of specific cGMP dependent protein kinases (PKG).
    • 别名
      • Cyclic GMP antibody
      • Cyclic guanosine monophosphate antibody
      • Guanosine 3 5 Cyclic Monophosphate antibody

    Anti-cGMP antibody 图像

    • ab12416 staining cGMP in SKNSH cells treated with 7-Chlorokynurenic acid sodium salt (ab120255), by ICC/IF. Decrease in cGMP expression correlates with increased concentration of 7-Chlorokynurenic acid sodium salt, as described in literature.
      The cells were incubated at 37°C for 30 minutes in media containing different concentrations of ab120255 (7-Chlorokynurenic acid sodium salt) in DMSO. Some samples where then further incubated with 15 μM NMDA (ab120052) for 5 minutes and all samples were fixed with 100% methanol for 5 minutes at -20°C and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab12416 (5 μg/ml) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 anti-rabbit polyclonal antibody (ab96899) at 1/250 dilution was used as the secondary antibody. Nuclei were counterstained with DAPI and are shown in blue.
    • ab12416 staining cGMP in SKNSH cells treated with 5,7-Dichlorokynurenic acid sodium salt (ab120254), by ICC/IF. Decrease in cGMP expression correlates with increased concentration of 5,7-Dichlorokynurenic acid sodium salt, as described in literature.
      The cells were incubated at 37°C for 20 minutes in media containing different concentrations of ab120254 (5,7-Dichlorokynurenic acid sodium salt) in DMSO. Some samples where then further incubated with 15 μM NMDA (ab120052) for 5 minutes and all samples were fixed with 100% methanol for 5 minutes at -20°C and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab12416 (5 μg/ml) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 anti-rabbit polyclonal antibody (ab96899) at 1/250 dilution was used as the secondary antibody. Nuclei were counterstained with DAPI and are shown in blue.
    • ab12416 staining cGMP in SKNSH cells treated with 7-Chlorokynurenic acid (ab120024), by ICC/IF. Decrease in cGMP expression correlates with increased concentration of 7-Chlorokynurenic acid, as described in literature.
      The cells were incubated at 37°C for 15 minutes in media containing different concentrations of ab120024 (7-Chlorokynurenic acid) in DMSO. Some samples where then further incubated with 15 μM NMDA (ab120052) for 5 minutes and all samples were fixed with 100% methanol for 5 minutes at -20°C and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab12416 (5 μg/ml) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 anti-rabbit polyclonal antibody (ab96899) at 1/250 dilution was used as the secondary antibody. Nuclei were counterstained with DAPI and are shown in blue.
    • ab12416 staining cGMP in SKNSH cells treated with 5,7-Dichlorokynurenic acid (ab120023), by ICC/IF. Decrease in cGMP expression correlates with increased concentration of 5,7-Dichlorokynurenic acid, as described in literature.
      The cells were incubated at 37°C for 20 minutes in media containing different concentrations of ab120023 (5,7-Dichlorokynurenic acid) in DMSO. Some samples where then further incubated with 15 μM NMDA (ab120052) for 5 minutes and all samples were fixed with 100% methanol for 5 minutes at -20°C and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab12416 (5 μg/ml) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 anti-rabbit polyclonal antibody (ab96899) at 1/250 dilution was used as the secondary antibody. Nuclei were counterstained with DAPI and are shown in blue.

    Anti-cGMP antibody (ab12416)参考文献

    This product has been referenced in:
    • Chang JC  et al. Receptor guanylyl cyclases in Inka cells targeted by eclosion hormone. Proc Natl Acad Sci U S A 106:13371-6 (2009). IHC-FoFr . Read more (PubMed: 19666575) »

    See 1 Publication for this product

    Product Wall

    Application Immunohistochemistry (Frozen sections)
    Sample Mouse Tissue sections (Brain (striatum))
    Specification Brain (striatum)
    Blocking step BSA as blocking agent for 2 hour(s) and 0 minute(s) · Concentration: 1% · Temperature: 21°C
    Fixative Paraformaldehyde
    Username

    Mr. Allen Pan

    Verified customer

    提交于 Feb 10 2014

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"